HDP-101 is under clinical development by Heidelberg Pharma and currently in Phase II for Relapsed Multiple Myeloma. According to GlobalData, Phase II drugs for Relapsed Multiple Myeloma have a 37% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how HDP-101’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

HDP-101 overview

HDP-101 is under development for the treatment of relapsed/refractory multiple myeloma and breast cancer. The therapeutic candidate constitutes a BCMA antibody targeting CD269 antigen conjugated to amanitin. It is administered through intravenous route.  It is being developed based on Amanitin ATAC technology.

The drug candidate was also under development for diffuse large B-cell lymphoma (DLBCL) and chronic lymphocytic leukaemia (CLL).

Heidelberg Pharma overview

Heidelberg Pharma is a biopharmaceutical company that develops novel therapeutics for the treatment and specific detection of various cancers. Heidelberg Pharma’s pipeline products are focused on treating multiple myeloma, prostate cancer, hematological cancers, non-hodgkin lymphoma, blood cancers, generic diseases and solid tumors. Through its subsidiary, Heidelberg Pharma Research GmbH provides preclinical contract research services and to develop the toxin Amanitin into oncology therapies using its proprietary Antibody Targeted Amanitin Conjugate (ATAC) technology platform. Heidelberg Pharma is headquartered in Ladenburg, Germany.

For a complete picture of HDP-101’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.